Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016

Схожие документы

• Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
  по: Akiho Fukuda, et al.
  Опубликовано: (2017-01-01)
• Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
  по: Fukuda, Akiho, et al.
  Опубликовано: (2017)
• Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
  по: Hasegawa, Shiori, et al.
  Опубликовано: (2017)
• Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
  по: Matsui, Toshinobu, et al.
  Опубликовано: (2017)
• Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events
  по: Sasaoka, Sayaka, et al.
  Опубликовано: (2016)